Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

ASCO GU 2022: The latest in CRPC, including PARP combo data

Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel...

ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )

Tailoring radiation therapy in the 21st century

Prof Philip Poortmans - University of Antwerp, Antwerp, Belgium

Tailoring radiation therapy in the 21st century ( Prof Philip Poortmans - University of Antwerp, Antwerp, Belgium )

Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL

Dr Juliana Pereira & Dr Steven Horwitz

Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL ( Dr Juliana Pereira & Dr Steven Horwitz )

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in...

Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pandemic strategising for cancer hospital stockpiles

Prof Richard Sullivan and Dr Aasim Yusuf

Pandemic strategising for cancer hospital stockpiles ( Prof Richard Sullivan and Dr Aasim Yusuf )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Update on the new EUSOMA quality indicators for breast cancer

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

Lung cancer in India

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India

Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )

The global impact of the FDA's changing approval standards

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The global impact of the FDA's changing approval standards ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz

Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )

ecancer-AORTIC special issue on cancer research training in Africa

Dr Solomon Rotimi - Covenant University, Ota, Nigeria

ecancer-AORTIC special issue on cancer research training in Africa ( Dr Solomon Rotimi - Covenant University, Ota, Nigeria )

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs...

Prof Peter Schmid - Queen Mary University of London, London, United Kingdom

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )

More from ecancer